TITLE:
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

CONDITION:
Bacterial Infections

INTERVENTION:
Zyvox / Linezolid

SUMMARY:

      This study will treat pediatric patients who have infections that are due to a specific
      bacteria (Vancomycin-Resistant Enterococcus)
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: N/A to 17 Years
Criteria:

        Other specific inclusion/exclusion criteria may apply. In order to determine eligibility,
        further examination by the investigator is necessary.

        Inclusion Criteria:

          -  Hospitalized/chronic care pediatric patients (birth through 17 years)

          -  Known infections due to vancomycin-resistant enterococcus species, including
             diagnosis of hospital-acquired pneumonia, complicated skin and skin structure
             infections, catheter-related bacteremia, bacteremia of unidentified source, and other
             infections

          -  Requires a minimum of 3 days of IV medication

          -  Patients with mixed infections due to VRE & gram negative bacteria are allowed to
             enroll in the study. For most of the infections, 2 or more of additional symptoms are
             required.

        Exclusion Criteria:

          -  Potentially effective concomitant antibiotic

          -  A high surgical cure rate

          -  Medical conditions which would preclude clinical evaluation or require treatment of
             longer duration than 28 days

          -  24 hours of antibiotic treatment within 48 hours of study entry (unless pre-approved)

          -  Having an infected device that could not be removed
      
